Palmieri (Therabel Gn Pharma), our management model is the company's strong point
“Pharmaceutical companies are divided into generics and Big Pharma. But we believe that there is a space within this large range, where we can try to build products with added value for doctors, but above all for patients". This was explained to Adnkronos Salute by the managing director of Therabel Gn Pharma, Robert Palmieri.
The Therabel group, a European multinational with 350 employees and a turnover of approximately 120 million euros, has had a subsidiary in Milan since 1997, born from the acquisition of GiEnne Pharma, a spin off of the Basf group. "We have developed - Palmieri points out - with the marketing of new products, but above all by consolidating our presence in specialist sectors such as cardiovascular, pain and oncology where, remaining open to new collaborations, we are recognized by the market as a specific competence".
The Milanese branch is therefore a medium-small company, which employs about a hundred people, has a turnover of 25 million euros, sells over 5 million packs of medicines a year and is in any case among the top 75 pharmaceutical companies in Italy . “The quality of the people who work in this company – points out the CEO – is its main characteristic, because they all have a particular aptitude which is entrepreneurship, and the shareholder has built on this. This has not only allowed us to absorb market turmoil, but has also allowed us to maintain the human dimension of our structure”.
Therabel GN Pharma has entered into partnerships with important international groups, such as Gebro Pharma for the marketing of an anti-inflammatory drug, with Abbott in the gastrointestinal field and at European level with Onyx, for the marketing of an antifungal that exploits a very innovative technology. Furthermore, in the field of anti-aldosterone drugs, thanks also to the implementation of innovative clinical research, it represents a point of reference for the entire cardiological sector.
"However - explains the CEO - we cannot hide the problems that the pharmaceutical sector is experiencing in our country. It is necessary to review the funding system in the pharmaceutical sector, which for two years has forced companies to clawback out of any market logic and guarantee regulatory stability in the medium term which allows companies to be able to plan investments. From this last point of view we appreciate the effort of this Government and of the Minister of Health in particular who, unlike others who preceded him, work on wide-ranging logics for the relaunch of this sector which is so strategic for our country".
BDC – March 27, 2015 – PharmaKronos
Related news: Palmieri (Therabel): 'glass houses' companies with certified data
